PETVOMI - FIX 4MG TABLET

Dual-Site 5-HT₃ Blockade The Most Targeted Antiemetic Mechanism:
Ondansetron's mechanism of action is among the most pharmacologically specific of all antiemetic drugs used in veterinary medicine. By selectively targeting the 5-HT₃ receptor rather than broadly antagonising multiple receptor types it achieves powerful anti-nausea and anti-vomiting effects with a markedly cleaner side effect profile than older antiemetics such as metoclopramide (dopamine antagonist) or chlorpromazine (phenothiazine). Veterinarians can use PetVomi Fix with confidence in patients where a targeted, receptor-specific antiemetic intervention is required, particularly when the emetic stimulus is primarily serotonergic in origin as is the case with most chemotherapy protocols and many gastrointestinal infections.

4 mg Strength Precision Dosing for Small-to-Medium Patients:
The 4 mg tablet strength of PetVomi Fix is deliberately designed for precise weight-based dosing in small-to-medium companion animals cats, small-breed dogs, and medium-breed dogs without the need for tablet halving or quartering that can compromise accurate dosing. Given that ondansetron is dosed by body weight (mg/kg), having an appropriate lower-strength tablet directly available ensures dosing accuracy and reduces the risk of under- or over-dosing in this size category. The 4 mg strength complements the 8 mg variant also available in the PetVomi Fix range, giving veterinarians dosing flexibility across a wide range of patient weights.

Palatable Chicken-Flavoured Tablet for Superior Compliance:
One of the most clinically significant challenges in companion animal pharmacotherapy particularly in cats is the refusal or active avoidance of oral medications. Cats are particularly medication-averse, and standard uncoated pharmaceutical tablets often require pilling aids, food hiding, or restraint techniques that cause animal distress and reduce client compliance with dosing schedules. PetVomi Fix's palatable chicken-flavoured tablet base directly addresses this challenge, significantly improving the ease and reliability of oral medication delivery. Improved palatability translates to improved dosing consistency, which translates directly to better therapeutic outcomes a benefit of practical importance in conditions requiring multi-day antiemetic courses.

Validated for Chemotherapy-Induced Emesis Drug of Choice:
Chemotherapy-associated nausea and vomiting (CINV) remains one of the most challenging clinical management problems in veterinary oncology. Serotonin release from enterochromaffin cells in the GI tract is a primary mediator of CINV, making 5-HT₃ receptor antagonists the mechanistically optimal pharmacological intervention. Ondansetron is well-established in the veterinary oncology literature as an effective and well-tolerated antiemetic for dogs and cats undergoing cytotoxic chemotherapy. PetVomi Fix Ondansetron 4 mg provides veterinary oncologists and general practitioners managing oncology patients with a reliably formulated, India-manufactured, cost-effective option for this demanding clinical application.

Broad Indication Profile Multiple Emetic Aetiologies:
PetVomi Fix is clinically indicated across a wide range of emetic presentations in both dogs and cats: severe acute vomiting from GI infections including parvoviral enteritis; vestibular disease-associated nausea; pancreatitis; chronic kidney disease (CKD)-associated nausea and vomiting in cats; perioperative (pre- and post-anaesthetic) nausea management; motion sickness in select cases; opioid-related pruritus (secondary to spinal or epidural opioid administration); and sleep apnoea management in brachycephalic breeds (e.g., Bulldogs). This breadth of application makes PetVomi Fix a versatile addition to any veterinary formulary or clinic's prescription antiemetic inventory.

Indian GMP Manufacture OriHeal Life Sciences
PetVomi Fix is manufactured by OriHeal Life Sciences Pvt. Ltd. an Indian veterinary pharmaceutical company ensuring that procurement, supply chain management, and regulatory compliance are aligned with Indian veterinary pharmaceutical standards. Domestic Indian manufacturing affords advantages in stock availability, pricing accessibility, and supply chain reliability compared to imported equivalents, making PetVomi Fix a pragmatic choice for Indian veterinary clinics and procurement officers managing formulary costs without compromising on pharmacological quality.

Rapid Onset Clinical Effect Within 1–2 Hours:
Oral ondansetron achieves measurable plasma concentrations within the therapeutic range within approximately 1–2 hours of administration in dogs and cats, providing timely relief from active nausea and vomiting in the clinical setting. This relatively rapid onset of action is particularly valuable in acute emetic presentations such as post-surgical recovery, active chemotherapy sessions, or acute GI infections where prompt emesis control improves patient comfort, reduces the risk of dehydration and electrolyte imbalance, and facilitates earlier return to voluntary food and water intake.

How to Use:

Administer the tablet orally, directly or concealed in a small amount of palatable food or a pill pocket to facilitate acceptance.

May be administered with or without food. If vomiting occurs when given on an empty stomach, administer with a small food offering at subsequent doses.

Ensure the patient swallows the tablet completely particularly important in cats who may hold the tablet before expectorating.

For pre-chemotherapy use, administer orally 30 minutes before cytotoxic agent administration; may be repeated every 8–12 hours as directed.

Fresh water should always be available during the treatment course.

Storage Instructions:

Store PetVomi Fix Ondansetron 4 mg Tablets in a cool, dry place between 2°C and 30°C (36°F–86°F), away from direct sunlight, heat, and moisture. Store in the original, tight, light-resistant packaging until point of use. Keep out of reach of children and non-target animals. Do not use beyond the printed expiry date. Tablets that appear discoloured, crumbled, or whose packaging has been compromised should not be dispensed.

About the Brand:

OriHeal Life Sciences Pvt. Ltd. is an Indian veterinary pharmaceutical company headquartered in New Delhi, dedicated to developing and manufacturing a comprehensive range of veterinary medicines spanning gastro-intestinal, ophthalmic, cardiac, and general medicine categories for companion and large animals. OriHeal's PetVomi Fix range available in both tablet and oral suspension formulations reflects the brand's commitment to making clinically important veterinary pharmaceuticals accessible to Indian veterinary professionals in well-formulated, palatable, and cost-effective presentations. OriHeal Life Sciences' commitment to quality veterinary pharmaceutical manufacturing and clinical relevance aligns perfectly with Animeal's mission to bring only the very best in veterinary pharmaceutical procurement to licensed veterinary professionals and registered clinics across India.

Disclaimer:

Ondansetron is an extra-label/off-label drug in veterinary medicine. Dosing, frequency, and duration of treatment must be individualised by a licensed veterinarian based on the patient's body weight, clinical diagnosis, organ function (particularly hepatic status), concurrent medications, and breed-specific genetic factors (MDR1 mutation). Serious adverse effects — though rare — may include constipation, mild sedation, extrapyramidal signs (head shaking), cardiac arrhythmias (QT prolongation), serotonin syndrome (when used concurrently with other serotonergic agents), and hypotension. Overdose in animals has been associated with sudden, transient loss of vision, severe constipation, and hypotension. If any adverse signs develop following administration, discontinue the medication and contact the attending veterinarian immediately. This product should not be used in pregnant or lactating animals without specific veterinary assessment of risk and benefit. Do not use in animals with known gastrointestinal obstruction or hypersensitivity to ondansetron.